In an observational study of the mass vaccination campaigns in Israel, real world effectiveness of the Pfizer vaccine 7 or more days after the second dose was 92% for documented SARS-CoV-2 infection, 94% for symptomatic infection, 87% for hospitalization, and 92% for severe disease. The study included 596,618 individuals matched to unvaccinated controls in a 1:1 ratio according to demographic and clinical characteristics.<\/p>\n
Vaccine effectiveness between 14 and 20 days after the first dose was 46%, 57%, 74%, 62%, and 72% in preventing any documented SARS-CoV-2 infection, symptomatic infection, hospitalization, severe disease, and death, respectively.<\/p>\n
The estimated vaccine effectiveness in preventing any infection among studied sub-populations was consistent across age groups, with potentially lower effectiveness in individuals with multiple co-existing conditions.<\/p>\n
Dagan et al.\u00a0(Feb 24, 2021). BNT162b2 MRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. New England Journal of Medicine. <\/i>https:\/\/doi.org\/10.1056\/NEJMoa2101765<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" In an observational study of the mass vaccination campaigns in Israel, real world effectiveness of the Pfizer vaccine 7 or more days after the second dose was 92% for documented SARS-CoV-2 infection, 94% for symptomatic infection, 87% for hospitalization, and 92% for severe disease. The study included 596,618 individuals matched to unvaccinated controls in a…<\/p>\n